SCHEMBL23364609

SCHEMBL23364609

CC(C)Oc1cccc(SCc2ccccc2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 1/20 0.49
PPARG P37231 2/20 0.48
PPARA Q07869 2/20 0.48
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
TTR P02766 1/20 0.41
MTNR1A P48039 3/20 0.41
MTNR1B P49286 3/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
SPHK2 Q9NRA0 1/20 0.41
SPHK1 Q9NYA1 1/20 0.41
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
RAB9A P51151 2/20 0.40
GABRA1 P14867 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29932889 1.00 SLC6A4 (0.49) SLC6A4PPARGPPARAMAOAMAOB
SCHEMBL3894912 0.82 MAOB (0.53) MAOBMTNR1AMTNR1BKMT2ARAB9A
SCHEMBL22492230 0.79 ACHE (0.51) PPARGPPARAMEN1KMT2A
SCHEMBL31187444 0.78 SPHK2 (0.59) MAOAMAOBSPHK2SPHK1
SCHEMBL27284258 0.76 SPHK2 (0.44) SLC6A4MAOAMAOBMEN1KMT2A
SCHEMBL30946574 0.76 SPHK2 (0.44) SLC6A4MAOAMAOBMEN1KMT2A
SCHEMBL28066945 0.75 SPHK2 (0.43) SLC6A4PPARGPPARAMAOAMAOB
SCHEMBL4929519 0.75 SLC6A4 (0.46) SLC6A4PPARGPPARAMAOAMAOB
SCHEMBL29114616 0.75 ABL1 (0.43) TTRMEN1KMT2ARAB9ANPC1
SCHEMBL29097762 0.75 KMT2A (0.53) MTNR1AMTNR1BMEN1KMT2ASPHK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION 2024-01-04 US disclosed
EP-4058439-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY Genzyme Corporation (US) 2022-09-21 EP disclosed
WO-2021097057-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY GENZYME CORPORATION (US) 2021-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240002374-A1 5-MEMBERED HETEROARYLAMINOSULFONAMIDES FOR TREATING CONDITIONS MEDIATED BY DEFICIENT CFTR ACTIVITY CFTR, PKD2, PKD1 SLC6A4 1827/4885PPARG 2472/4885PPARA 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.